Craig M. Rush
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Craig M. Rush has a total of 89 co-authors. Here are the top co-authors by number of shared publications:
- Jason Gertz
Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah 84112, USA
76 shared publications - Jeffery M. Vahrenkamp
Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah 84112, USA
75 shared publications - David H. Lum
Preclinical Research Resource, Huntsman Cancer Institute, University of Utah
72 shared publications - Zannel Blanchard
Department of Oncological Sciences, Huntsman Cancer Institute, University of Utah
72 shared publications - Spencer Arnesen
Department of Oncological Sciences, Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah
71 shared publications - Adriana Cristina Rodriguez
Department of Neurobiology, University of Utah, Salt Lake City, UT, USA
70 shared publications
Latest Publications
- 17 July 2026
- Published by Cold Spring Harbor Laboratory in Genome Research
- Vol. 36 (9) , 1771-1784
Identification of genomic features that uniquely impact estrogen receptor alpha binding and its effects on gene expression in endometrial cancer
Estrogen receptor 1 (ESR1, also known as estrogen receptor alpha or ER) is an established oncogenic transcription factor in breast and endometrial cancer; however, more is known about the mechanisms controlling ER behavior in breast cancer, and therapies targeting ER have been much more successful in breast cancer. To address this disparity, we characterize the genomic features that control ER in endometrial cancer and determine to what extent these factors differ from those in breast cancer. We focus on the locations of estrogen response elements (EREs), ER's preferred DNA-binding motif, throughout the human genome. To identify factors that predict ER genomic binding and effects on target gene expression, we apply machine learning to genomic data for each ERE in Ishikawa cells (ER-positive endometrial cancer) and T-47D cells (ER-positive breast cancer). Many of these factors, such as chromatin accessibility and histone modifications, are predictive of ER activity in both cell lines. However, the transcription factors that predict ER activity are cell type specific, including FOXA1 and GATA3 in T-47D cells and ETV4 and SOX17 in Ishikawa cells. In addition, the features that predict ER binding and effects on gene expression differ, with transcription at EREs in the absence of estrogen being predictive of ER regulatory activity. A CRISPR knockout screen in Ishikawa cells, as well as follow-up experiments, confirms the discovery that SOX17 controls ER activity in endometrial cancer cells. These results identify important genomic features of ER binding and regulatory activity and how these features differ between endometrial cancer and breast cancer cells.
- 17 July 2026
- Published by Cold Spring Harbor Laboratory in Genome Research
- Vol. 36 (9) , 1771-1784
Identification of genomic features that uniquely impact estrogen receptor alpha binding and its effects on gene expression in endometrial cancer
Estrogen receptor 1 (ESR1, also known as estrogen receptor alpha or ER) is an established oncogenic transcription factor in breast and endometrial cancer; however, more is known about the mechanisms controlling ER behavior in breast cancer, and therapies targeting ER have been much more successful in breast cancer. To address this disparity, we characterize the genomic features that control ER in endometrial cancer and determine to what extent these factors differ from those in breast cancer. We focus on the locations of estrogen response elements (EREs), ER's preferred DNA-binding motif, throughout the human genome. To identify factors that predict ER genomic binding and effects on target gene expression, we apply machine learning to genomic data for each ERE in Ishikawa cells (ER-positive endometrial cancer) and T-47D cells (ER-positive breast cancer). Many of these factors, such as chromatin accessibility and histone modifications, are predictive of ER activity in both cell lines. However, the transcription factors that predict ER activity are cell type specific, including FOXA1 and GATA3 in T-47D cells and ETV4 and SOX17 in Ishikawa cells. In addition, the features that predict ER binding and effects on gene expression differ, with transcription at EREs in the absence of estrogen being predictive of ER regulatory activity. A CRISPR knockout screen in Ishikawa cells, as well as follow-up experiments, confirms the discovery that SOX17 controls ER activity in endometrial cancer cells. These results identify important genomic features of ER binding and regulatory activity and how these features differ between endometrial cancer and breast cancer cells.
- Open Access
Identification of genomic features that uniquely impact estrogen receptor alpha binding and its effects on gene expression in endometrial cancer
Estrogen receptor alpha (ER) is an established oncogenic transcription factor in breast and endometrial cancer; however, more is known about the mechanisms controlling ER behavior in breast cancer, and therapies targeting ER have been much more successful in breast cancer. To address this disparity, we sought to identify genomic features that control ER in endometrial cancer and determine to what extent these factors differ from those in breast cancer. We focused on the locations of estrogen response elements (EREs), ER's preferred DNA binding motif, throughout the human genome. To identify factors that predict ER genomic binding and effects on target gene expression, we applied machine learning to genomic data for each ERE in Ishikawa cells (ER+ endometrial cancer) and T-47D cells (ER+ breast cancer). Many of these factors, such as chromatin accessibility and histone modifications, were predictive of ER activity in both cell lines. However, the transcription factors that predict ER activity were found to be cell type-specific, including FOXA1 and GATA3 in T-47D cells, and ETV4 and SOX17 in Ishikawa cells. In addition, the features that predict ER binding and effects on gene expression differed, with transcription at EREs in the absence of estrogen being predictive of regulatory activity. To verify our findings in the Ishikawa cells, we performed a CRISPR knockout screen, which confirmed the discovery that SOX17 controls ER activity in endometrial cancer cells. These results identify important genomic features of ER binding and regulatory activity and how these features differ between endometrial cancer and breast cancer cells.
Open AccessIdentification of genomic features that uniquely impact estrogen receptor alpha binding and its effects on gene expression in endometrial cancer
Estrogen receptor alpha (ER) is an established oncogenic transcription factor in breast and endometrial cancer; however, more is known about the mechanisms controlling ER behavior in breast cancer, and therapies targeting ER have been much more successful in breast cancer. To address this disparity, we sought to identify genomic features that control ER in endometrial cancer and determine to what extent these factors differ from those in breast cancer. We focused on the locations of estrogen response elements (EREs), ER's preferred DNA binding motif, throughout the human genome. To identify factors that predict ER genomic binding and effects on target gene expression, we applied machine learning to genomic data for each ERE in Ishikawa cells (ER+ endometrial cancer) and T-47D cells (ER+ breast cancer). Many of these factors, such as chromatin accessibility and histone modifications, were predictive of ER activity in both cell lines. However, the transcription factors that predict ER activity were found to be cell type-specific, including FOXA1 and GATA3 in T-47D cells, and ETV4 and SOX17 in Ishikawa cells. In addition, the features that predict ER binding and effects on gene expression differed, with transcription at EREs in the absence of estrogen being predictive of regulatory activity. To verify our findings in the Ishikawa cells, we performed a CRISPR knockout screen, which confirmed the discovery that SOX17 controls ER activity in endometrial cancer cells. These results identify important genomic features of ER binding and regulatory activity and how these features differ between endometrial cancer and breast cancer cells.
- Open Access
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Supplemental Figure 4 from Allele-Specific Gene Regulation, Phenotypes, and Therapeutic Vulnerabilities in Estrogen Receptor Alpha–Mutant Endometrial Cancer
ER mutants do not affect proliferation, but down-regulate proteins associated with movement and impact migration
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure 4 from Allele-Specific Gene Regulation, Phenotypes, and Therapeutic Vulnerabilities in Estrogen Receptor Alpha–Mutant Endometrial Cancer
ER mutants do not affect proliferation, but down-regulate proteins associated with movement and impact migration
- Open Access
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Supplemental Figure 6 from Allele-Specific Gene Regulation, Phenotypes, and Therapeutic Vulnerabilities in Estrogen Receptor Alpha–Mutant Endometrial Cancer
Identification of novel therapeutic targets in ER active and mutant endometrial cancer
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure 6 from Allele-Specific Gene Regulation, Phenotypes, and Therapeutic Vulnerabilities in Estrogen Receptor Alpha–Mutant Endometrial Cancer
Identification of novel therapeutic targets in ER active and mutant endometrial cancer
- Open Access
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Supplemental Table 5 from Allele-Specific Gene Regulation, Phenotypes, and Therapeutic Vulnerabilities in Estrogen Receptor Alpha–Mutant Endometrial Cancer
Enrichment values for ER associating proteins in endometrial and breast cancer cell lines
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Table 5 from Allele-Specific Gene Regulation, Phenotypes, and Therapeutic Vulnerabilities in Estrogen Receptor Alpha–Mutant Endometrial Cancer
Enrichment values for ER associating proteins in endometrial and breast cancer cell lines
- Open Access
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Supplemental Figure 1 from Allele-Specific Gene Regulation, Phenotypes, and Therapeutic Vulnerabilities in Estrogen Receptor Alpha–Mutant Endometrial Cancer
Validation and gene expression analysis of ER mutant models
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure 1 from Allele-Specific Gene Regulation, Phenotypes, and Therapeutic Vulnerabilities in Estrogen Receptor Alpha–Mutant Endometrial Cancer
Validation and gene expression analysis of ER mutant models
- Open Access
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Supplemental Figure 2 from Allele-Specific Gene Regulation, Phenotypes, and Therapeutic Vulnerabilities in Estrogen Receptor Alpha–Mutant Endometrial Cancer
Comparison of mutant ER regulated genes and genes regulated by sustained estrogen signaling
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure 2 from Allele-Specific Gene Regulation, Phenotypes, and Therapeutic Vulnerabilities in Estrogen Receptor Alpha–Mutant Endometrial Cancer
Comparison of mutant ER regulated genes and genes regulated by sustained estrogen signaling
- Open Access
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Supplemental Table 4 from Allele-Specific Gene Regulation, Phenotypes, and Therapeutic Vulnerabilities in Estrogen Receptor Alpha–Mutant Endometrial Cancer
Mutant ESR1 generation: gBlock used for template amplification
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Table 4 from Allele-Specific Gene Regulation, Phenotypes, and Therapeutic Vulnerabilities in Estrogen Receptor Alpha–Mutant Endometrial Cancer
Mutant ESR1 generation: gBlock used for template amplification
- Open Access
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Supplemental Table 1 from Allele-Specific Gene Regulation, Phenotypes, and Therapeutic Vulnerabilities in Estrogen Receptor Alpha–Mutant Endometrial Cancer
Differentially expressed genes from in vitro RNA-seq experiments
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Table 1 from Allele-Specific Gene Regulation, Phenotypes, and Therapeutic Vulnerabilities in Estrogen Receptor Alpha–Mutant Endometrial Cancer
Differentially expressed genes from in vitro RNA-seq experiments
- Open Access
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Supplemental Table 2 from Allele-Specific Gene Regulation, Phenotypes, and Therapeutic Vulnerabilities in Estrogen Receptor Alpha–Mutant Endometrial Cancer
Overlap between prolonged E2 treatment and differentially expressed genes in vitro
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Table 2 from Allele-Specific Gene Regulation, Phenotypes, and Therapeutic Vulnerabilities in Estrogen Receptor Alpha–Mutant Endometrial Cancer
Overlap between prolonged E2 treatment and differentially expressed genes in vitro